Retatrutide in the UK has no licence and no release date. The MHRA said on 15 October 2026: "Retatrutide has not been authorised for use in the UK."

What has the MHRA said about retatrutide in the UK?

The statement followed a £2 million raid in Birmingham. The MHRA added that products sold as retatrutide outside legitimate clinical trials were being supplied outside the applicable rules and presented public-health risks.

Has Lilly filed for retatrutide in the UK?

The sources for this page give no UK date. Lilly's stated plan is for the US. Manufacturing Chemist reported on 24 July 2026 that Lilly planned a US regulatory submission in early 2027. The same report says the data could support global submissions, without giving dates.

What would a UK licence need?

An application and an MHRA decision. Neither has been reported, and an FDA decision would not cover the UK. The mechanism page covers what the molecule is.

Any launch date quoted for retatrutide in the UK is a guess for now.

Scope for European readers

This is a dated account of the research or policy described in the linked sources. The stated jurisdiction, study product and population matter. A US or UK announcement does not establish authorisation or availability across Europe. Nothing in this report establishes results for an EPS catalogue material. Read the research-use statement for the storefront's scope.